Bayer Pharma Aktiengesellschaft

Jörg Heiermann

Karl-Heinz Schlemmer

Joachim Schuhmacher

Susanne Röhrig

Yolanda Cancho Grande

Johannes Köbberling

Michael Sperzel

Nils Burkhardt

Christian Stegmann

Manuel Ellermann

Tom Kinzel

Maria Köllnberger

Jorma Haßfeld

Kristin Beyer

Matthias Werner

Jan Stampfuß

Imke Meyer

Willem Jan Hengeveld

Gaelle Valot

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Piperidinylpyrazolopyrimidinones and their use

Growing community of inventors

Wesel, Germany

Jörg Heiermann